Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 06/19/2015 - 04/20/2018

This course is closed. Please look for other available products in CPNP University.

Target Audience

This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

According to the results from the 2012 National Survey on Drug Use and Health (NSDUH) - Mental Health Findings report, the relationship between increased substance abuse and acute mental illness is starkly clear. Greater than 10% of the U.S. adult population reported illicit substance use in the past year, a number that more than doubled to 26.7% for the adult mental health population. This disparity was consistent regardless of the type of substance being abused, whether illegal agents (i.e., heroin, cocaine) or non-medical use of prescription drugs.

Because trends in substance use change over time, identifying current substances of concern is helpful to guide practice interventions. Because of the strong relationship between mental illness and substance abuse, it is especially important for pharmacists practicing in mental health settings to stay abreast of substance abuse trends. Mike O’Neil, PharmD, will discuss the impact of the prescription and illicit substance abuse problem on healthcare systems, including pharmacists in the mental health setting, as well as obstacles providers in mental health settings may face when treating patients with substance use disorders.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Faculty Information and Disclosures

Learning Objectives

  1. Explain the scope of substance use disorders associated with prescription medications and the impact on healthcare systems and the mental health community.
  2. Examine the impact of existing diversion programs in reducing substance abuse based on current trends.
  3. Distinguish obstacles to treatment faced by providers in any mental health setting related to prescription /illicit substance abuse.
  4. Evaluate potential abuse of prescription medications not historically recognized as drugs of concern.

Continuing Education Credit and Disclosures

Activity Dates: 06/19/2015 - 04/20/2018
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-15-009-H04-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 1.0 contact hours (0.10 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-15-009-H04-P (1.0 contact hours).

Grant Support

This activity is partially supported by an educational grant from Sunovion Pharmaceuticals, Inc.